Gsk (GSK) FCF Payout Ratio (QoQ) (2009 - 2026)
Gsk (GSK) FCF Payout Ratio (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn |
| 10 | Novartis Ag | 112.59 Bn | 111.90 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -115.64% |
| Dec 31, 2025 | 40.37% |
| Sep 30, 2025 | 33.20% |
| Jun 30, 2025 | -17.51% |
| Mar 31, 2025 | -951.94% |
| Dec 31, 2024 | 85.30% |
| Sep 30, 2024 | 28.64% |
| Jun 30, 2024 | 11.09% |
| Mar 31, 2024 | -1,607.10% |
| Dec 31, 2023 | 87.30% |
| Sep 30, 2023 | 58.81% |
| Jun 30, 2023 | 56.64% |
| Mar 31, 2023 | 93.62% |
| Dec 31, 2022 | -2,060.04% |
| Mar 31, 2022 | -274.73% |
| Dec 31, 2021 | -129.47% |
| Sep 30, 2021 | 26.22% |
| Jun 30, 2021 | 96.91% |
| Mar 31, 2021 | -628.80% |
| Dec 31, 2020 | 51.49% |